1. Illumina for cell analysis.

2. A specialized Thermo Fisher Scientific for advanced cell profiling.

• Aurora and Northern Lights systems: Spectrum flow cytometers that deliver cell analysis by utilizing fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
• Aurora Cell Sorter system: A system leveraging full spectrum profiling technology to broaden potential applications across cell analysis through cell sorting.
• Reagents and Kits: Includes cFluor reagents (fluorochrome conjugated antibodies for cell identification) and a 25-color immunoprofiling assay (a turnkey solution for identifying major human immune subpopulations).
• Automated Micro-sampling and Sample Loader systems: Automated plate loaders designed to integrate seamlessly into their Aurora and Northern Lights systems for efficient sample handling.
• SpectroFlo software: Intuitive software providing workflow solutions from quality control to data analysis for their Aurora and Northern Lights systems.
• Customer Support Tools: Resources and services provided to assist customers with their products and ensure optimal performance.

• Pharmaceutical and biopharma companies
• Academic research centers
• Clinical research organizations

Wenbin Jiang, Ph.D. Chief Executive Officer and Chairman of the Board

Dr. Wenbin Jiang is a co-founder of Cytek Biosciences and has served as its Chief Executive Officer and a member of the Board since December 2014. Prior to Cytek, Dr. Jiang co-founded E2O Communications, Inc., a fiber optic subsystems manufacturing company, in 1998. E2O Communications was subsequently acquired by JDS Uniphase Corporation in 2004. He is also an accomplished inventor, holding over 95 U.S. patents and authoring numerous technical papers and book chapters.

William McCombe Chief Financial Officer

William McCombe was appointed Chief Financial Officer of Cytek Biosciences in March 2024. He brings extensive experience as a public company CFO, having held the position at Velo3D, HZO, and serving as EVP and CFO at Maxar Technologies. Mr. McCombe also has a significant background in investment banking, with over 20 years of experience, including roles as a Managing Director at Morgan Stanley and Bank of America.

Ming Yan, Ph.D. Chief Technology Officer

Dr. Ming Yan is a co-founder of Cytek Biosciences and has served as its Chief Technology Officer and a member of the Board since 2015. He possesses over 20 years of experience in research and development, with previous roles at AT&T Bell Laboratories, Lawrence Livermore National Labs, and BD Biosciences.

Valerie Barnett Chief Legal Officer and Corporate Secretary

Valerie Barnett serves as the Chief Legal Officer and Corporate Secretary for Cytek Biosciences.

Philippe Busque, Ph.D. Senior Vice President, Global Sales & Services

Dr. Philippe Busque holds the position of Senior Vice President of Global Sales & Services at Cytek Biosciences.

Key Risks to Cytek Biosciences (CTKB)

Cytek Biosciences, Inc. (CTKB) faces several key risks that could impact its business operations and financial performance. These risks are primarily related to external market conditions, internal operational efficiencies, and supply chain vulnerabilities.

1. Challenging Capital Equipment Spending and Funding Uncertainties: A significant risk for Cytek Biosciences is the "softness" in capital equipment spending, particularly within the academic and government sectors, especially in the United States. This is directly linked to funding uncertainties, such as those related to National Institutes of Health (NIH) funding policies. This market condition has directly contributed to declines in instrument sales in certain regions and acts as a major headwind for the company, offsetting gains in other areas. Customer demand is pressured by these external factors, leading to reduced instrument sales in academic and government segments.
2. Operational Efficiency Challenges and Pressure on Profitability: Cytek Biosciences has experienced considerable pressure on its profitability and operational efficiency. The company's gross margin has been under strain, with reports of a decline, and it has shifted from reporting net income to net losses in recent periods. This margin compression is attributed to factors such as higher materials and tariff costs, increased headcount, and elevated operating expenses, including litigation-related costs. These challenges indicate difficulties in translating revenue growth into sustainable profits and efficient cash flow generation.
3. Dependence on Sole and Single-Source Suppliers: Cytek Biosciences relies on a limited number of, and in some cases, sole or single-source suppliers for critical components of its instruments, such as certain lasers and semiconductors. These specialized parts are fundamental to the optical, electrical, and fluidic subassemblies of their core products. This dependency exposes the company to risks of increased input costs, potential supply shortages, and significant lead times required to identify and qualify alternative suppliers should a single-source provider fail or experience disruptions.

Cytek Biosciences (CTKB) operates in the cell analysis solutions market, with its main products encompassing flow cytometry instruments, reagents, and associated software and automated systems. The company's addressable markets can be primarily segmented into the broader cell analysis market, and more specifically, the flow cytometry instruments and flow cytometry reagents markets.

The global cell analysis market was estimated at approximately $34.3 billion in 2025 and is projected to reach $81.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2033. Another estimate places the global cell analysis market size at $39.22 billion in 2026, with a projection to reach $93.23 billion by 2034, exhibiting a CAGR of 11.43% during 2026–2034. North America held the largest share of the global cell analysis market, accounting for 40.0% in 2025. The Asia-Pacific region is anticipated to be the fastest-growing market, with a CAGR of 13.1% from 2026 to 2033.

For the more specific flow cytometry market, which is central to Cytek's offerings, the global market size was approximately $6.13 billion in 2025, growing to $6.59 billion in 2026, and is expected to reach around $12.97 billion by 2035, at a CAGR of 7.78% from 2026 to 2035. Other estimates for the global flow cytometry market include a projection to reach $9.85 billion by 2033 from $5.06 billion in 2025, with a CAGR of 8.7% from 2025 to 2033. Additionally, the global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a CAGR of 8.2% from 2024 to 2029. North America held the largest share of the flow cytometry market, at 39.76% in 2025 and 41.9% in 2024. The Asia-Pacific region is also a significant growth area, projected to achieve a CAGR of 8.35% from 2026 to 2035.

Within the flow cytometry market, the instruments segment is a key component of Cytek's business. The global flow cytometry instrument market size is projected to be approximately $4.44 billion in 2026 and is expected to reach about $9.59 billion by 2035, growing at a CAGR of 8.8%. North America accounts for approximately 42% of the global flow cytometry instrument market share, while Europe holds about 29% and Asia-Pacific contributes 22% of global installations.

The market for flow cytometer reagents, including Cytek's cFluor reagents, was estimated at approximately $3.33 billion in 2024. This market is projected to grow from $3.64 billion in 2025 to $8.77 billion by 2035, with a CAGR of 9.2% during this period. North America is a leader in the flow cytometer reagents market, holding approximately $1.67 billion in 2024. The Asia-Pacific region's reagents market was valued at approximately $0.55 billion in 2024 and is experiencing rapid growth. In 2024, reagents and consumables collectively accounted for the largest share, 54.0%, of the flow cytometry market. Cytek estimates an annual addressable market of $150 million for non-Cytek reagents currently used in its more than 3,000 installed instruments.

Here are 3-5 expected drivers of future revenue growth for Cytek Biosciences (CTKB) over the next 2-3 years:

1. Growth in Recurring Revenue from Services and Reagents: Cytek Biosciences anticipates continued strong growth in its recurring revenue streams, particularly from services and reagents. This growth is directly tied to an expanding global installed base of Cytek instruments, which reached 2,247 instruments in Q1 2024 and 3,456 units as of September 30, 2025. As more instruments are placed, the demand for associated services and cFluor reagents, which are used to identify cells of interest for analysis on its instruments, increases. Management expects recurring revenue as a share of total revenue to continue growing.
2. New Product Launches and Product Innovation: The introduction of innovative new products, such as the Cytek Aurora Evo system and the Muse Micro System, is expected to drive future revenue growth. The Aurora Evo system, for instance, has already contributed to significant unit growth in the combined Aurora category. Cytek also leverages its full spectrum profiling technology and aims to maintain leadership in instruments.
3. Geographic Expansion and Market Recovery: Cytek Biosciences is experiencing and expects continued momentum from its global expansion efforts and market recoveries in key regions. Strong demand and double-digit growth in instrument sales and overall revenue have been observed in the Asia-Pacific (APAC) region, including China. Additionally, the company has noted a rebound and improved market environment in the Europe, Middle East, and Africa (EMEA) region and stabilization in the U.S. market, particularly among academic and government customers.
4. Expansion into Clinical Applications and the Clinical Business: Cytek is strategically expanding its clinical business, especially in Europe and APAC, by pursuing regulatory clearances for its products, such as 510(k) and IVDR clearances. This focus aims to move its Full Spectrum Profiling technology into routine clinical applications, such as leukemia and lymphoma monitoring, thereby accessing a significant portion of the flow cytometry market. The company has already received China National Medical Products Association (NMPA) approval for a single-laser 6-color TBNK panel and registered 18 single-color reagents for IVD use in China for clinical applications.